Biosimilars: Extrapolating the evidence. A roundtable discussion  by Monk, Bradley J. et al.
ww.sciencedirect.com
E J C S u p p l e m en t s 1 3 ( 2 0 1 5 ) 1e2Available online at wScienceDirect
journal homepage: www.ejcancer .comWebcast reportBiosimilars: Extrapolating the evidence. A
roundtable discussionBradley J. Monk a,*, Morton Coleman b, Philip Lammers c, George Somlo d
a University of Arizona Cancer Center, Phoenix, AZ, USA
b New York Presbyterian Hospital/Weill Cornell Medical Center, New York, NY, USA
c Meharry Medical College, Nashville, TN, USA
d City of Hope Comprehensive Cancer Center, Duarte, CA, USAa r t i c l e i n f o
Article history:
Received 10 December 2015
Accepted 12 December 2015* Corresponding author: E-mail addresses: B
http://dx.doi.org/10.1016/j.ejcsup.2015.12.001
1359-6349/© 2015 Published by Elsevier Ltd. T
licenses/by-nc-nd/4.0/).anticancer therapies are currently licensed for use across
tumor types and in supportive care.biosimilarity and extrapolation. They provide practical insightBiological anticancer therapies developed in recent decades
have contributed to improvements in patient care for serious
illnesses. Patents for several biologics will soon expire, paving
the way for initiating approval processes for bio-
similarsddefined as highly similar versions of already
licensed or approved biological therapies. The aim of devel-
oping a biosimilar is to establish similarity in terms of quality,
safety, and efficacy rather than to reestablish clinical benefit.
Fundamentally if two products are highly similar, all aspects
of their therapeutic effects (ie, safety, immunogenicity, and
efficacy) should also be highly similar. This introduces a
different way of thinking about drug development for clini-
cians, who will ultimately analyze and integrate biosimilars
into existing treatment paradigms. As such, oncologists
across specialties need to understand the core concepts of
biosimilarity, including extrapolationdthe approval of a bio-
similar for use in an indication held by the previously
approved biological therapy (deemed the reference product),
but not directly studied in a comparative clinical trial with the
biosimilar. Extrapolation is the highly scrutinized scientific
rationale that bridges data collected across indications and
has important implications in oncology, where biologicalradley.monk@chw.edu, D
his is an open access artIn this roundtable discussion, experts specializing in
breast, lung, hematologic, and gynecologic cancers highlight
the scientific and clinical rationale behind establishment of
into the implications of biosimilars for clinical practices,
including their potential to expand global access to important
medicines for patients and clinicians.Financial support
This webcast and webcast report were made possible by
funding from Pfizer Biosimilars. All items are subject to in-
dependent peer and editorial review.Conflict of interest
 Bradley J. Monk, MD
e Research Grants: Amgen, Array, Genentech, Janssen/
Johnson & Johnson, Lilly, Morphotek, Tesaro
e Speakers Bureau: AstraZeneca, Myriad, Roche/
Genentech
e Advisory: Advaxis, Amgen, AstraZeneca, Bayer, Ceru-
lean, Gradalis, ImmunoGen, Merck, NuCana, Pfizer,
Roche/Genentech, Tesaro, Verastem, Vermillion
 Morton Coleman, MD
e Research Grants: Amgen, Bayer, Celgene, Gilead, Glaxo-
SmithKline, Karyopharm, Pfizeraniele.Sumner@chw.edu (B.J. Monk).
icle under the CC BY-NC-ND license (http://creativecommons.org/
E J C S u p p l em en t s 1 3 ( 2 0 1 5 ) 1e22e Speakers Bureau: Celgene, Gilead, Johnson & Johnson,
Pharmacyclics
e Advisory: Celgene, Gilead, Onyx, Pfizer
 Philip Lammers, MD
e Research Grants: None
e Speakers Bureau: None
e Advisory: Pfizer, Boehringer-Ingelheim
 George Somlo, MD
e Research Grants: Celgene, Rochee Speakers Bureau: Celgene, Pharmacyclics, Takeda
e Advisory: Celgene, Nanostring, Novartis, Pfizer, TakedaSupplementary data
The webcast associated with this webcast report can be found
in online form at http://biosimilarswebcast.elsevierresource.
com.
